RECIST and iRECIST Comparison in a Cohort of Patients with Advanced NSCLC Treated with Immunotherapy: Preliminary Study

被引：0
|
作者：
Garcia Martinez, F. [1 ]
Fernandez-Velilla Pena, M. [2 ]
Cruz Castellanos, P. [1 ]
De Castro Carpeno, J. [1 ]
Pertejo, A. [1 ]
Torres Sanchez, I. [1 ]
机构：
[1] Hosp Univ La Paz, Radiodiagnost, Madrid, Spain
[2] Hosp Univ La Paz, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Immunotherapy; RECIST; iRECIST;
D O I：
10.1016/j.jtho.2019.08.2152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.04-30
引用
收藏
页码：S980 / S980
页数：1
相关论文
共 50 条
  • [21] Genetic and Immunological Backgrounds in Advanced NSCLC Patients Treated with Immunotherapy - NGS and Flow Cytometry Analysis
    Krzyzanowska, N.
    Nicos, M.
    Wojas-Krawczyk, K.
    Krawczyk, P.
    Chmielewska, I.
    Jankowski, T.
    Kucharczyk, T.
    Wojcik-Superczynska, M.
    Sroka-Bartnicka, A.
    Stokowy, T.
    Milanowski, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S330 - S331
  • [22] Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront
    Jimenez, J. Torres
    Gorria, T.
    Auclin, E.
    Castro, N.
    Albarran-Artahona, V.
    Ruffinelli, J. C.
    Pinato, D.
    Routy, B.
    Nana, F. Aboubakar
    Reyes, R.
    Vinolas, N.
    Blanc-Durand, F.
    Lopes, G.
    Nadal, E.
    Arasanz, H.
    Pascal, M.
    Teixido, C.
    Besse, B.
    Reguart, N.
    Mezquita, L.
    Jimenez, J. Torres
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S385 - S386
  • [23] Comparison of RECIST to Immune Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor
    Kim, Hee Kyung
    Lee, Hansang
    Heo, Mi Hwa
    Cho, Jinhyun
    Park, Ju Youn
    Jeong, Su-Mi
    Sun, Jong -Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1294 - S1295
  • [24] Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
    Kim, Jung Han
    ONCOTARGET, 2016, 7 (12) : 13680 - 13687
  • [25] Efficacy of immunotherapy in Chinese patients with KRASmutant advanced NSCLC
    Wang, Z.
    Han, X.
    Peng, L.
    Guo, J.
    Kong, L.
    Huang, Y.
    Tang, N.
    Zhang, J.
    Wang, M.
    He, X.
    Li, Z.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1067 - S1067
  • [26] Predictors of outcomes in patients with NSCLC treated with chemoradiotherapy & immunotherapy
    Horne, A.
    Shortall, J.
    Mcwilliam, A.
    Faivre-Finn, C.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1049 - S1051
  • [27] Immunotherapy (I) for advanced, pre-treated, non-squamous NSCLC (APNS-NSCLC): Preliminary data of a pooled analysis.
    Morriconi, Ilaria
    Cherubini, Chiara
    Tamburini, Emiliano
    Papi, Maximiliam
    Fantini, Manuela
    Bianchi, Emanuela
    Gianni, Lorenzo
    Carminati, Ornella
    Pasini, Giuseppe
    Arcangeli, Valentina
    Nicolini, Mario
    Gianni, Caterina
    Lazzari, Luigi
    Tassinari, Davide
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
    Tazdait, M.
    Mezquita, L.
    Lahmar, J.
    Ferrara, R.
    Bidault, F.
    Ammari, S.
    Balleyguier, C.
    Planchard, D.
    Gazzah, A.
    Soria, J. C.
    Marabelle, A.
    Besse, B.
    Caramella, C.
    EUROPEAN JOURNAL OF CANCER, 2018, 88 : 38 - 47
  • [29] Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade
    Arbour, Kathryn C.
    Luu, Anh Tuan
    Luo, Jia
    Rizvi, Hira
    Plodkowski, Andrew J.
    Sakhi, Mustafa
    Huang, Kevin B.
    Digumarthy, Subba R.
    Ginsberg, Michelle S.
    Girshman, Jeffrey
    Kris, Mark G.
    Riely, Gregory J.
    Yala, Adam
    Gainor, Justin F.
    Barzilay, Regina
    Hellmann, Matthew D.
    CANCER DISCOVERY, 2021, 11 (01) : 59 - 67
  • [30] Preliminary results of the "Blue Sky Radiomics" study on stage III NSCLC patients treated with chemo-radiation and consolidation immunotherapy
    Filippi, A. R.
    Lancia, A.
    Oneta, O.
    Tsoutzidis, N.
    Bortolotto, C.
    Ali, E.
    Bartolomeo, V.
    La Mattina, S.
    Borghetti, P.
    Stella, G.
    Agustoni, F.
    Sun, R.
    Deutsch, E.
    Lascialfari, A.
    Figini, S.
    Pedrazzoli, P.
    Preda, L.
    Walsh, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S85 - S85
12345